Rahul Khara, serving as the Chief Legal Officer for Disc Medicine, Inc. (NASDAQ:IRON), reported the sale of 7,500 shares of the company's common stock on June 18, 2026. The total value of these sales reached $526,660. These transactions were conducted under the framework of a Rule 10b5-1 trading plan, which Mr. Khara adopted on March 19, 2026. The sales followed the exercise of stock options for an equivalent number of shares, a process that also occurred on the same day.
The stock transactions were executed at weighted average prices ranging from $69.35 to $71.81 per share. The breakdown of the sales includes 5,400 shares sold at prices between $69.35 and $70.34, 1,600 shares sold at prices between $70.40 and $71.38, and 500 shares sold at prices between $71.45 and $71.81. Prior to these sales, Mr. Khara acquired 7,500 shares of Disc Medicine common stock by exercising stock options at a price of $14.69 per share, totaling $110,175. The options were fully vested and exercisable at the time of the transaction.
Following these transactions, Mr. Khara directly holds 52,173 shares of Disc Medicine, Inc. common stock. The stock has demonstrated significant volatility, with a beta of 2.1 and a 52-week range of $40 to $99.50. At the time of the reporting, IRON shares traded at $70.45, up 28% over the past year despite recent volatility. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, with the company carrying a market cap of $2.7 billion.
In other recent developments, Disc Medicine Inc. presented updated clinical trial data for two investigational treatments at the European Hematology Association Annual Meeting. The RALLY-MF trial, involving DISC-0974, enrolled 61 adult patients with myelofibrosis and anemia, with 50 patients included in the responder analysis. Additionally, Disc Medicine completed a Type A meeting with the U.S. Food and Drug Administration regarding bitopertin for erythropoietic protoporphyria. The FDA indicated that the ongoing Phase 3 APOLLO study could potentially support a traditional approval if successful.
Stifel reiterated a Buy rating for Disc Medicine, highlighting the efficacy of DISC-0974 in the Phase 2 RALLY-MF trial. Furthermore, Disc Medicine launched an expanded access program for bitopertin, targeting patients with erythropoietic protoporphyria and X-linked protoporphyria in the U.S. This program is available to eligible patients who meet specific criteria and lack satisfactory therapeutic alternatives. The company's market position remains under scrutiny as it navigates clinical advancements and regulatory pathways.